SAN CARLOS, Calif., Feb. 5, 2014 /PRNewswire/ — Rosa & Co. LLC, a drug development advisory firm with expertise in drug-disease modeling and simulation, today announced the appointment of Ananth Kadambi, PhD, as Senior Vice President, PhysioPD, to manage their rapidly-expanding business in Japan and Asia.
(Logo: http://photos.prnewswire.com/prnh/20140205/PH59278LOGO)
"We are pleased to add Dr. Kadambi to the Rosa management team. His extensive executive experience and unique scientific expertise are an excellent fit for Rosa and our clients," said Rosa CEO Ron Beaver, PhD. "His leadership will be particularly important as we expand our scientific collaborations with customers in Asia."
Dr. Kadambi brings over 15 years of business, scientific, and drug-disease modeling experience to Rosa. Previously, at Evidera, a strategic consulting firm, he was the Director of Modeling and Simulation Development. There, he served as principal investigator for multiple pharmaceutical client research collaborations in health economics, and he was responsible for the development of innovative internal modeling initiatives. Prior to Evidera, Dr. Kadambi was Vice President at Entelos Holdings, Inc., where he led the modeling and simulation R&D division. During his time at Entelos, Dr. Kadambi was a senior scientist and director, responsible for leading R&D projects, managing research collaborations, and providing scientific expertise in customer research collaborations. His expertise spans several therapeutic areas, including cardiovascular biology, oncology, inflammatory diseases, and immunology. Dr. Kadambi received his PhD in Biomedical Engineering from the University of Virginia. He performed postdoctoral research in oncology at both Massachusetts General Hospital and the University of California, San Francisco.
About Rosa
Rosa helps clients better understand complex biology and inform their critical decisions – from preclinical through clinical development – with the creation and use of flexible mathematical models that simulate normal and disease physiology, drug action, patient variability, and trial outcomes. Rosa offers both PhysioPD™ Research Platforms and classic pharmacokinetic/pharmacodynamic (PK/PD) models. Rosa's clients participate in customized model development and testing processes, retain the resulting models, and acquire the ability to perform simulation research to better understand implications for their pharmaceutical, consumer, and veterinary product development programs. Rosa has unparalleled experience in applying modeling and simulation to better understand biology and accelerate product development and is unique in its breadth and depth of disease area experience, including metabolic, cardiovascular, oncology, inflammation, immune dysfunction, CNS, respiratory, dermatology, nutrition, and antibacterial/antiviral biology. For more information, visit www.rosaandco.com.
Media Contact:
Sharan Pagano
978-995-2805